Uwe Rix
- Hematology top 1%
- Chronic Myeloid Leukemia Treatments 16
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 14
- Pharmacology top 1%
- Microbial Natural Products and Biosynthesis 12
- Oncology top 2%
- Cancer-related Molecular Pathways 7
- Molecular Biology top 2%
- PI3K/AKT/mTOR signaling in cancer 10
- Protein Degradation and Inhibitors 7
-
- Lung Cancer Treatments and Mutations 11
-
- Advanced Proteomics Techniques and Applications 11
- Co-authors
- Giulio Superti‐FurgaLily L. Remsing RixOliver HantschelKeiryn L. BennettJacques ColingeJürgen RohrPeter ValentEric B. Haura
- Cited by
- HematologyGeneticsPharmacology
- Partner nations
- United StatesAustriaGermany
In The Last Decade
Uwe Rix
89 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Hematology 901
- Genetics 753
- Pharmacology 833
- Oncology 1.0k
- Molecular Biology 2.6k
Countries citing papers authored by Uwe Rix
This map shows the geographic impact of Uwe Rix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Uwe Rix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Uwe Rix more than expected).
Fields of papers citing papers by Uwe Rix
This network shows the impact of papers produced by Uwe Rix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Uwe Rix. The network helps show where Uwe Rix may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Uwe Rix, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 8 | |
| 2 | 2021 | 19 | |
| 3 | 2021 | 64 | |
| 4 | 2021 | 6 | |
| 5 | 2019 | 69 | |
| 6 | 2019 | 122 | |
| 7 | 2017 | 13 | |
| 8 | 2017 | 61 | |
| 9 | 2016 | 21 | |
| 10 | 2016 | 18 | |
| 11 | 2016 | 77 | |
| 12 | 2014 | 20 | |
| 13 | 2014 | 34 | |
| 14 | 2011 | 32 | |
| 15 | 2010 | 18 | |
| 16 | 2010 | 219 | |
| 17 | Target profiling of small molecules by chemical proteomicsbreakdown → | 2008 | 463 |
| 18 | 2003 | 113 | |
| 19 | 2003 | 50 | |
| 20 | 2000 | 74 |
About Uwe Rix
Uwe Rix is a scholar working on Hematology, Genetics and Oncology, having authored 89 papers that have together received 4.9k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (16 papers), Chronic Lymphocytic Leukemia Research (14 papers), Microbial Natural Products and Biosynthesis (12 papers), Lung Cancer Treatments and Mutations (11 papers), Advanced Proteomics Techniques and Applications (11 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Cancer-related Molecular Pathways (7 papers) and Protein Degradation and Inhibitors (7 papers). The work is most often cited by research in Hematology (901 citations), Genetics (753 citations) and Pharmacology (833 citations). Uwe Rix has collaborated with scholars based in United States, Austria and Germany. Frequent co-authors include Giulio Superti‐Furga, Lily L. Remsing Rix, Oliver Hantschel, Keiryn L. Bennett, Jacques Colinge, Jürgen Rohr, Peter Valent, Eric B. Haura, Lily L. Remsing and John M. Koomen. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Cancer Research, Nature Chemical Biology and Journal of Proteome Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.